Deuterated Tryptamine Derivatives for Selective Oral 5-HT2A Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing serotonin 5-HT2 receptor agonists face challenges in selectivity, leading to undesirable psychedelic effects and neurotoxicity, while also having low bioavailability and oral activity, necessitating improved formulations for controlled delivery.
Innovation Solution
Development of deuterated tryptamine derivatives that selectively modulate 5-HT2A receptors, reducing psychedelic effects and enhancing bioavailability through enzymatic degradation slowing and increased blood-brain ratio, allowing for once-daily dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classic serotonergic psychedelics are used to activate 5-HT2A receptors, then therapeutic effects are achieved, but psychedelic effects and neurotoxicity occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by introducing deuterium atoms at specific positions on the tryptamine molecule (particularly on the phenyl ring at positions 4 and/or 5, and/or on the ethylamine chain), creating localized isotopic substitution that selectively modulates receptor interaction and enzymatic metabolism without changing the overall molecular structure. This localized modification achieves enhanced 5-HT2A selectivity while reducing off-target effects.
Solution Approach 2:
The patent employs parameter changes by substituting hydrogen atoms with deuterium atoms (changing the isotopic composition parameter), which alters the kinetic isotope effect on C-H bond cleavage rates. This parameter change slows down enzymatic degradation by cytochrome P450 enzymes, extending the compound's half-life and allowing for once-daily dosing while maintaining selective 5-HT2A receptor engagement.
2Use of energy by moving object
If high doses of tryptamines are administered to achieve therapeutic effects, then receptor activation is sufficient, but toxicity and psychedelic effects increase
Solution Approach 1:
The deuterated tryptamine derivatives utilize the kinetic isotope effect (parameter change in bond strength and cleavage rate) to extend plasma half-life from minutes to hours. This allows maintaining therapeutic receptor activation at lower, safer doses, as the compound remains active longer in the system, reducing the need for high peak concentrations that cause toxicity.
Solution Approach 2:
The deuterated compounds provide continuous therapeutic action through once-daily dosing, maintaining steady plasma concentrations that continuously engage 5-HT2A receptors without the need for multiple daily doses or high peak concentrations, thereby eliminating toxic effects while preserving therapeutic efficacy.
3Ease of operation
If tryptamines are administered orally, then convenience is improved, but first-pass metabolism renders them orally inactive
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen with deuterium at metabolically labile positions, which slows the rate of C-H bond cleavage by cytochrome P450 enzymes during first-pass metabolism. This kinetic isotope effect preserves the compound from rapid degradation, enabling sufficient oral bioavailability for therapeutic use.
Solution Approach 2:
The patent converts the harmful effect of extensive first-pass metabolism into a benefit by using deuterium substitution to protect the compound from degradation. The same enzymatic pathways that normally rapidly metabolize tryptamines are slowed by the deuterium effect, transforming first-pass metabolism from a liability into a controllable parameter that can be managed with once-daily dosing.
4Duration of action of moving object
If frequent dosing is used to maintain therapeutic levels, then receptor engagement is continuous, but patient compliance and convenience decrease
Solution Approach 1:
The deuterated tryptamine derivatives extend the duration of action by slowing enzymatic degradation, increasing plasma half-life from minutes to 12-24 hours or longer. This parameter change enables once-daily dosing while maintaining continuous therapeutic receptor engagement, significantly improving patient compliance and convenience.
Solution Approach 2:
The deuterated compounds provide continuous useful action through extended half-life, maintaining therapeutic plasma concentrations throughout the dosing interval. This continuous action ensures sustained 5-HT2A receptor engagement without requiring multiple daily doses, resolving the contradiction between duration of action and dosing frequency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The deuterated tryptamine derivatives provide selective engagement of 5-HT2A receptors without psychedelic effects, improving oral bioavailability and reducing neurotoxicity, offering therapeutic benefits for various disorders.
Implementation Method 1
The compounds of formula (I) and compounds of formula (II) and pharmaceutically acceptable salts, solvates, and prodrugs thereof have extended plasma half-lives and improved oral bioavailability compared to their non-deuterated counterparts
Data Source
AI summary
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.